| SAINT LAURENT, Quebec, May 29, 2012 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCBB:IGXT) ("IntelGenx") today announced the completion of the pivotal bioequivalence study for a novel oral thin-film formulation of Rizatriptan, the active drug in Maxalt-MLT® orally disintegrating tablets. Maxalt-MLT® is a leading branded anti-migraine product manufactured by Merck & Co. According to Merck's most recent annual report, sales of Maxalt® grew 16% to $639 million in 2011. The thin-f...continued IGX:CA IGXT shares pharmaceuticals formulation |
SmallCapUpdates provides the latest news and alerts on stocks for you. If you are looking for the latest on stocks in clean energy, medical innovation, mining, biotech, nanotech, renewable energy, internet technology or in emerging markets.
Pages
▼
No comments:
Post a Comment